No Data
No Data
Kangmei Pharmaceuticals' 2024 semi-annual report
Summary of Kangmei Pharmaceutical's 2024 semi-annual report
Dealing with inefficient and ineffective assets to promote debt-for-equity swaps, Kangmei Pharmaceutical (600518.SH) turned its half-year loss into a profit of 15.7603 million yuan.
Kangmei Pharmaceutical (600518.SH) released the semi-annual report for 2024, with the company achieving revenue of 2...
Should Weakness in Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Does Kangmei Pharmaceutical (SHSE:600518) Have A Healthy Balance Sheet?
Announcement of Kangmei Pharmaceuticals' expected half-year performance in 2024.
No Data